Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Apathy | 17 | 2023 | 47 | 6.330 |
Why?
|
Alzheimer Disease | 21 | 2023 | 367 | 4.710 |
Why?
|
Methylphenidate | 14 | 2023 | 94 | 4.330 |
Why?
|
Veterans | 14 | 2023 | 629 | 2.940 |
Why?
|
Central Nervous System Stimulants | 11 | 2023 | 255 | 2.830 |
Why?
|
Pandemics | 8 | 2021 | 579 | 2.500 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 184 | 2.460 |
Why?
|
Coronavirus Infections | 5 | 2020 | 192 | 2.420 |
Why?
|
Transcranial Magnetic Stimulation | 3 | 2020 | 81 | 1.880 |
Why?
|
Depressive Disorder | 7 | 2020 | 368 | 1.750 |
Why?
|
Activities of Daily Living | 8 | 2023 | 204 | 1.360 |
Why?
|
Psychotic Disorders | 4 | 2023 | 144 | 1.350 |
Why?
|
Videoconferencing | 2 | 2020 | 40 | 1.260 |
Why?
|
Stress Disorders, Post-Traumatic | 4 | 2023 | 394 | 1.170 |
Why?
|
Caregivers | 6 | 2020 | 241 | 1.160 |
Why?
|
Aged | 35 | 2023 | 10054 | 1.120 |
Why?
|
Depression | 6 | 2020 | 595 | 1.070 |
Why?
|
Affective Symptoms | 2 | 2020 | 22 | 1.000 |
Why?
|
Humans | 69 | 2023 | 54284 | 0.980 |
Why?
|
Social Isolation | 3 | 2021 | 29 | 0.980 |
Why?
|
Double-Blind Method | 8 | 2023 | 742 | 0.900 |
Why?
|
Antipsychotic Agents | 5 | 2022 | 247 | 0.900 |
Why?
|
Dementia | 3 | 2023 | 149 | 0.880 |
Why?
|
Quinolones | 3 | 2007 | 35 | 0.870 |
Why?
|
Time Perception | 2 | 2020 | 30 | 0.860 |
Why?
|
Male | 43 | 2023 | 27334 | 0.840 |
Why?
|
Schizophrenia | 2 | 2023 | 276 | 0.840 |
Why?
|
Piperazines | 3 | 2007 | 116 | 0.830 |
Why?
|
World War II | 1 | 2021 | 11 | 0.830 |
Why?
|
Anxiety | 3 | 2020 | 279 | 0.820 |
Why?
|
Awards and Prizes | 1 | 2021 | 20 | 0.810 |
Why?
|
Narration | 1 | 2021 | 31 | 0.810 |
Why?
|
Executive Function | 2 | 2018 | 80 | 0.790 |
Why?
|
Rural Health | 1 | 2020 | 102 | 0.730 |
Why?
|
Research Subjects | 1 | 2020 | 58 | 0.710 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2022 | 231 | 0.700 |
Why?
|
Music | 1 | 2018 | 7 | 0.680 |
Why?
|
Auditory Perception | 1 | 2018 | 29 | 0.670 |
Why?
|
Prefrontal Cortex | 1 | 2018 | 89 | 0.650 |
Why?
|
Sleep Apnea Syndromes | 1 | 2018 | 31 | 0.650 |
Why?
|
Loneliness | 4 | 2021 | 13 | 0.640 |
Why?
|
Biomedical Research | 2 | 2020 | 240 | 0.630 |
Why?
|
Telemedicine | 2 | 2020 | 449 | 0.610 |
Why?
|
Cross-Sectional Studies | 7 | 2020 | 1693 | 0.550 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 132 | 0.550 |
Why?
|
Antidepressive Agents | 2 | 2020 | 187 | 0.540 |
Why?
|
Pilot Projects | 6 | 2023 | 808 | 0.540 |
Why?
|
Middle Aged | 24 | 2022 | 13088 | 0.540 |
Why?
|
Independent Living | 4 | 2020 | 46 | 0.530 |
Why?
|
Female | 30 | 2023 | 28441 | 0.520 |
Why?
|
Neuropsychological Tests | 3 | 2016 | 363 | 0.510 |
Why?
|
Treatment Outcome | 12 | 2023 | 5604 | 0.500 |
Why?
|
Cognition | 7 | 2020 | 348 | 0.490 |
Why?
|
Aged, 80 and over | 13 | 2021 | 3431 | 0.490 |
Why?
|
Depressive Disorder, Major | 3 | 2022 | 159 | 0.480 |
Why?
|
Psychiatric Status Rating Scales | 4 | 2007 | 346 | 0.460 |
Why?
|
User-Computer Interface | 3 | 2021 | 93 | 0.450 |
Why?
|
Bipolar Disorder | 2 | 2022 | 211 | 0.430 |
Why?
|
Brain | 3 | 2020 | 1387 | 0.430 |
Why?
|
Cognition Disorders | 4 | 2012 | 240 | 0.420 |
Why?
|
Citalopram | 2 | 2012 | 19 | 0.400 |
Why?
|
Suicide, Attempted | 2 | 2022 | 73 | 0.380 |
Why?
|
Motivation | 2 | 2010 | 291 | 0.370 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2020 | 43 | 0.360 |
Why?
|
Occupational Exposure | 2 | 2021 | 129 | 0.350 |
Why?
|
Mental Disorders | 3 | 2013 | 451 | 0.340 |
Why?
|
Blood Glucose | 2 | 2012 | 489 | 0.330 |
Why?
|
Diabetes Mellitus | 2 | 2012 | 309 | 0.310 |
Why?
|
Combat Disorders | 1 | 2007 | 42 | 0.310 |
Why?
|
Resistance Training | 3 | 2018 | 102 | 0.310 |
Why?
|
Prospective Studies | 7 | 2020 | 2604 | 0.300 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2007 | 24 | 0.300 |
Why?
|
Gambling | 1 | 2007 | 19 | 0.300 |
Why?
|
Bupropion | 1 | 2007 | 30 | 0.300 |
Why?
|
Mood Disorders | 1 | 2007 | 63 | 0.300 |
Why?
|
Urinary Retention | 1 | 2006 | 7 | 0.300 |
Why?
|
Syndrome | 3 | 2020 | 252 | 0.290 |
Why?
|
Risperidone | 1 | 2006 | 25 | 0.290 |
Why?
|
Exercise Therapy | 2 | 2019 | 123 | 0.290 |
Why?
|
Domestic Violence | 1 | 2006 | 24 | 0.290 |
Why?
|
Benzhydryl Compounds | 1 | 2007 | 75 | 0.280 |
Why?
|
Emotions | 1 | 2007 | 168 | 0.280 |
Why?
|
Patient Compliance | 1 | 2007 | 249 | 0.270 |
Why?
|
Attitude to Health | 1 | 2007 | 226 | 0.270 |
Why?
|
Sex Offenses | 1 | 2006 | 82 | 0.260 |
Why?
|
Walking | 4 | 2020 | 110 | 0.260 |
Why?
|
Psychiatry | 1 | 2007 | 116 | 0.260 |
Why?
|
Military Personnel | 2 | 2020 | 174 | 0.260 |
Why?
|
Arkansas | 2 | 2021 | 2100 | 0.250 |
Why?
|
Geriatric Assessment | 4 | 2015 | 126 | 0.250 |
Why?
|
Students, Medical | 1 | 2007 | 173 | 0.240 |
Why?
|
Fructose | 1 | 2023 | 29 | 0.240 |
Why?
|
Risk Factors | 4 | 2022 | 3935 | 0.230 |
Why?
|
Clinical Competence | 1 | 2007 | 446 | 0.230 |
Why?
|
Suicidal Ideation | 2 | 2022 | 96 | 0.230 |
Why?
|
Accidental Falls | 2 | 2017 | 98 | 0.220 |
Why?
|
Dietary Supplements | 2 | 2018 | 449 | 0.220 |
Why?
|
Muscle, Skeletal | 3 | 2018 | 847 | 0.210 |
Why?
|
Lithium | 1 | 2022 | 40 | 0.210 |
Why?
|
Energy Intake | 2 | 2012 | 196 | 0.200 |
Why?
|
Time Factors | 5 | 2018 | 3213 | 0.200 |
Why?
|
Severity of Illness Index | 3 | 2017 | 1084 | 0.200 |
Why?
|
Hospitals, Veterans | 2 | 2015 | 127 | 0.200 |
Why?
|
Air Pollutants, Occupational | 1 | 2020 | 18 | 0.190 |
Why?
|
Appointments and Schedules | 1 | 2020 | 28 | 0.190 |
Why?
|
Electronic Mail | 1 | 2020 | 19 | 0.190 |
Why?
|
Buprenorphine | 1 | 2022 | 132 | 0.190 |
Why?
|
Geriatric Psychiatry | 1 | 2020 | 11 | 0.190 |
Why?
|
Neuroimaging | 2 | 2018 | 88 | 0.190 |
Why?
|
Medical Staff | 1 | 2020 | 6 | 0.190 |
Why?
|
Receptors, Dopamine | 1 | 2020 | 21 | 0.190 |
Why?
|
Europe | 1 | 2020 | 102 | 0.190 |
Why?
|
Geriatrics | 1 | 2020 | 47 | 0.190 |
Why?
|
Jogging | 1 | 2020 | 2 | 0.190 |
Why?
|
Fear | 2 | 2020 | 87 | 0.180 |
Why?
|
Trazodone | 1 | 2020 | 6 | 0.180 |
Why?
|
Aspartic Acid | 1 | 2020 | 48 | 0.180 |
Why?
|
Weight Loss | 2 | 2012 | 271 | 0.180 |
Why?
|
Brain Chemistry | 1 | 2020 | 75 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 150 | 0.180 |
Why?
|
Research Personnel | 1 | 2020 | 69 | 0.170 |
Why?
|
Patient Safety | 1 | 2020 | 121 | 0.170 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 253 | 0.170 |
Why?
|
Thigh | 1 | 2018 | 40 | 0.160 |
Why?
|
Postural Balance | 2 | 2017 | 61 | 0.160 |
Why?
|
Exercise | 2 | 2020 | 552 | 0.160 |
Why?
|
Adult | 6 | 2023 | 14207 | 0.160 |
Why?
|
Stress, Psychological | 1 | 2020 | 270 | 0.160 |
Why?
|
Opioid-Related Disorders | 1 | 2022 | 367 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2018 | 8 | 0.160 |
Why?
|
Medication Therapy Management | 1 | 2018 | 24 | 0.160 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 119 | 0.160 |
Why?
|
Delivery of Health Care | 1 | 2020 | 327 | 0.150 |
Why?
|
Comorbidity | 2 | 2018 | 663 | 0.150 |
Why?
|
Cross-Over Studies | 1 | 2018 | 250 | 0.150 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 137 | 0.150 |
Why?
|
Sensation Disorders | 1 | 2017 | 14 | 0.150 |
Why?
|
Follow-Up Studies | 2 | 2020 | 2387 | 0.140 |
Why?
|
Rehabilitation Centers | 2 | 2012 | 37 | 0.140 |
Why?
|
Edema | 2 | 2014 | 74 | 0.130 |
Why?
|
Risk Assessment | 1 | 2020 | 1361 | 0.130 |
Why?
|
Immune System | 1 | 2015 | 49 | 0.130 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2015 | 44 | 0.130 |
Why?
|
Adaptation, Physiological | 1 | 2015 | 101 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 486 | 0.120 |
Why?
|
Clinical Protocols | 1 | 2015 | 122 | 0.120 |
Why?
|
Nursing Homes | 1 | 2015 | 126 | 0.120 |
Why?
|
United States | 5 | 2022 | 5217 | 0.120 |
Why?
|
RNA, Messenger | 1 | 2018 | 1202 | 0.120 |
Why?
|
Feasibility Studies | 1 | 2015 | 398 | 0.120 |
Why?
|
Amyloid beta-Peptides | 1 | 2014 | 82 | 0.120 |
Why?
|
Hospital Units | 1 | 2012 | 13 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 1213 | 0.110 |
Why?
|
Physical Endurance | 1 | 2012 | 49 | 0.110 |
Why?
|
Leg | 1 | 2012 | 130 | 0.110 |
Why?
|
Fluoxetine | 1 | 2012 | 47 | 0.110 |
Why?
|
Directive Counseling | 1 | 2011 | 24 | 0.100 |
Why?
|
Arthritis, Rheumatoid | 1 | 2013 | 130 | 0.100 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 240 | 0.100 |
Why?
|
Malnutrition | 1 | 2012 | 83 | 0.100 |
Why?
|
Recovery of Function | 1 | 2012 | 222 | 0.100 |
Why?
|
Video Games | 1 | 2011 | 13 | 0.100 |
Why?
|
Aging | 2 | 2018 | 784 | 0.100 |
Why?
|
Weight Gain | 1 | 2012 | 243 | 0.100 |
Why?
|
Weight Reduction Programs | 1 | 2011 | 65 | 0.100 |
Why?
|
Mianserin | 1 | 2010 | 8 | 0.090 |
Why?
|
Hallucinations | 1 | 2010 | 18 | 0.090 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2010 | 31 | 0.090 |
Why?
|
Rural Population | 1 | 2015 | 600 | 0.090 |
Why?
|
Dietary Proteins | 1 | 2012 | 230 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2012 | 635 | 0.090 |
Why?
|
Retrospective Studies | 2 | 2020 | 6432 | 0.090 |
Why?
|
Inflammation | 1 | 2012 | 674 | 0.080 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2007 | 39 | 0.080 |
Why?
|
Drive | 1 | 2007 | 4 | 0.080 |
Why?
|
Nebraska | 1 | 2007 | 7 | 0.080 |
Why?
|
Dementia, Vascular | 1 | 2007 | 6 | 0.070 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 50 | 0.070 |
Why?
|
Alcohol Withdrawal Seizures | 1 | 2006 | 1 | 0.070 |
Why?
|
Alcohol Withdrawal Delirium | 1 | 2006 | 2 | 0.070 |
Why?
|
Alcoholic Beverages | 1 | 2006 | 6 | 0.070 |
Why?
|
Simvastatin | 1 | 2006 | 35 | 0.070 |
Why?
|
Cost of Illness | 1 | 2007 | 133 | 0.070 |
Why?
|
Interviews as Topic | 1 | 2007 | 319 | 0.070 |
Why?
|
Self Care | 1 | 2007 | 147 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 426 | 0.070 |
Why?
|
Tobacco Use Disorder | 1 | 2007 | 184 | 0.060 |
Why?
|
Alcoholism | 1 | 2007 | 249 | 0.060 |
Why?
|
Body Mass Index | 1 | 2007 | 713 | 0.060 |
Why?
|
Cholinesterase Inhibitors | 1 | 2023 | 25 | 0.060 |
Why?
|
Mental Status Schedule | 2 | 2017 | 19 | 0.060 |
Why?
|
Obesity | 1 | 2011 | 1202 | 0.060 |
Why?
|
Aftercare | 1 | 2023 | 81 | 0.050 |
Why?
|
Antimanic Agents | 1 | 2022 | 14 | 0.050 |
Why?
|
Narcotic Antagonists | 1 | 2022 | 127 | 0.050 |
Why?
|
Incineration | 1 | 2021 | 6 | 0.050 |
Why?
|
Hypesthesia | 1 | 2020 | 18 | 0.050 |
Why?
|
Internship and Residency | 1 | 2007 | 501 | 0.050 |
Why?
|
Patient Discharge | 1 | 2023 | 353 | 0.050 |
Why?
|
Memory Disorders | 1 | 2020 | 62 | 0.050 |
Why?
|
RNA, Viral | 1 | 2021 | 141 | 0.050 |
Why?
|
Impulsive Behavior | 1 | 2020 | 82 | 0.050 |
Why?
|
Gait | 1 | 2020 | 98 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2020 | 244 | 0.040 |
Why?
|
Organ Size | 1 | 2018 | 237 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 48 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 91 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 501 | 0.040 |
Why?
|
Adipose Tissue | 1 | 2018 | 207 | 0.040 |
Why?
|
Neurobiology | 1 | 2016 | 5 | 0.040 |
Why?
|
Video Recording | 1 | 2017 | 90 | 0.040 |
Why?
|
Quality of Life | 1 | 2023 | 922 | 0.040 |
Why?
|
Off-Label Use | 1 | 2015 | 27 | 0.030 |
Why?
|
Psychomotor Agitation | 1 | 2015 | 53 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 596 | 0.030 |
Why?
|
Bone and Bones | 1 | 2018 | 516 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2014 | 28 | 0.030 |
Why?
|
tau Proteins | 1 | 2014 | 30 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 139 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 2014 | 62 | 0.030 |
Why?
|
Intermediate Care Facilities | 1 | 2012 | 6 | 0.030 |
Why?
|
Prealbumin | 1 | 2012 | 24 | 0.030 |
Why?
|
Serum Albumin | 1 | 2012 | 62 | 0.030 |
Why?
|
Regional Blood Flow | 1 | 2012 | 121 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2012 | 80 | 0.030 |
Why?
|
Phosphorylation | 1 | 2014 | 614 | 0.030 |
Why?
|
Cholesterol | 1 | 2012 | 155 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2012 | 159 | 0.030 |
Why?
|
Nutritional Status | 1 | 2012 | 158 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 322 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2013 | 643 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2012 | 315 | 0.020 |
Why?
|
Young Adult | 1 | 2020 | 4318 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 434 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2013 | 746 | 0.020 |
Why?
|
Body Weight | 1 | 2012 | 578 | 0.020 |
Why?
|
Cohort Studies | 1 | 2012 | 1543 | 0.020 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2006 | 7 | 0.020 |
Why?
|
Pharmacy Service, Hospital | 1 | 2006 | 17 | 0.020 |
Why?
|
Drug Utilization | 1 | 2006 | 74 | 0.020 |
Why?
|
Central Nervous System Depressants | 1 | 2006 | 78 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2006 | 195 | 0.020 |
Why?
|
Sex Factors | 1 | 2007 | 767 | 0.020 |
Why?
|
Ethanol | 1 | 2006 | 322 | 0.010 |
Why?
|
Age Factors | 1 | 2007 | 1198 | 0.010 |
Why?
|